Now, in eLife, Ingo Mellinghoff of the Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues—including Igor Vivanco and Zhi Chen as joint first authors—address this issue by examining how two different types of AKT inhibitor regulate the survival of cancer cells. This evidence concerns the gene AKT1 and cancer.